SCHEMBL7195201

SCHEMBL7195201

COC(=O)c1cccc(C=O)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ERN1 O75460 6/20 0.56
TLR2 O60603 1/20 0.56
TLR1 Q15399 1/20 0.56
TLR6 Q9Y2C9 1/20 0.56
LMNA P02545 1/20 0.52
TSHR P16473 1/20 0.52
ALDH1A1 P00352 3/20 0.49
POLB P06746 2/20 0.49
RAB9A P51151 1/20 0.49
PIM1 P11309 1/20 0.48
PIM3 Q86V86 1/20 0.48
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CFTR P13569 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5198420 0.84 KDM4E (0.57) KDM4EL3MBTL1LMNATSHRALDH1A1
SCHEMBL121356 0.83 LMNA (0.57) KDM4ELMNATSHRALDH1A1POLB
SCHEMBL30635255 0.83 LMNA (0.57) KDM4ELMNATSHRALDH1A1POLB
SCHEMBL1538293 0.82 TSHR (0.65) KDM4EL3MBTL1LMNATSHRALDH1A1
SCHEMBL16566856 0.82 ALDH1A1 (0.59) KDM4EL3MBTL1ERN1TLR2TLR1
SCHEMBL26617428 0.82 CA1 (0.50) KDM4EL3MBTL1ERN1TLR2TLR1
SCHEMBL31184600 0.82 ALDH1A1 (0.59) KDM4EL3MBTL1ERN1TLR2TLR1
SCHEMBL29216778 0.82 ALDH1A1 (0.49) KDM4EL3MBTL1ERN1TLR2TLR1
Benzene SCHEMBL28217563 0.81 TSHR (0.55) KDM4ELMNATSHRALDH1A1POLB
SCHEMBL1092958 0.81 CA1 (0.50) KDM4EL3MBTL1ERN1TLR2TLR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1246273-A None JP disclosed
CN-108602811-B FXR receptor agonists 轩竹生物科技有限公司 2021-11-16 CN disclosed
EP-3212647-B1 NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) DONG A ST CO LTD (KR) 2019-04-03 EP disclosed
EP-3212647-B1 NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) DONG A ST CO LTD (KR) 2019-04-03 EP disclosed
EP-2928879-B1 PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARM SPA (IT) 2018-02-28 EP disclosed
EP-2928880-B1 PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARM SPA (IT) 2018-02-14 EP disclosed
US-9890151-B2 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-02-13 US disclosed
US-9834550-B2 Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) DONG-A ST CO., LTD. (KR) 2017-12-05 US disclosed
US-9834550-B2 Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) DONG-A ST CO., LTD. (KR) 2017-12-05 US disclosed
US-9834550-B2 Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) DONG-A ST CO., LTD. (KR) 2017-12-05 US disclosed
US-20140155427-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2014-06-05 US disclosed
US-20140155428-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A (IT) 2014-06-05 US disclosed
US-6593315-B2 For controlling phytopathogenic harmful fungi BASF AKTIENGESELLSCHAFT (DE) 2003-07-15 US disclosed
US-20020032178-A1 Salicylic acid derivatives, processes for their preparation, compositions comprising them, their use BASF AKTIENGESELLSCHAFT (DE) 2002-03-14 US disclosed
US-4882340-A INHIBITS REFLECTIVE CONTRACTION OF URINARY BLADDER TANABE SEIYAKU CO., LTD. (JP) 1989-11-21 US disclosed
JP-H01246273-A DIHYDROBENZOFURANONE DERIVATIVE KISSEI PHARMACEUT CO LTD 1989-10-02 JP disclosed
US-4829067-A INHIBITORS OF REFLECTIVE CONTRACTION OF BLADDER TANABE SEIYAKU CO., LTD. (JP) 1989-05-09 US disclosed
CN-1031840-A Benzofuran derivative and preparation method thereof TANABE SEIYAKU CO (JP) 1989-03-22 CN disclosed
EP-0306226-A2 A benzofuran derivative and processes for preparing the same Tanabe Seiyaku Co., Ltd. (JP) 1989-03-08 EP disclosed
EP-0270342-A2 A benzo-furan (or -thiophene) derivative and processes for preparing the same Tanabe Seiyaku Co., Ltd. (JP) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155427-A1 NOVEL COMPOUNDS CHRM3, PDE4A, PDE3A KDM4E 2743/4885L3MBTL1 2711/4885ERN1 2238/4885
US-20140155428-A1 NOVEL COMPOUNDS PDE4A, CHRM3, PDE4B KDM4E 2661/4885L3MBTL1 2741/4885ERN1 2145/4885
US-20020032178-A1 Salicylic acid derivatives, processes for their preparation, compositions comprising them, their use NOD1, HAO1, HAAO KDM4E 3550/4885L3MBTL1 4244/4885ERN1 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.